Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1038)	10/5/2001 11:33:52 AM
From: tuck	Read Replies (1) \| Respond to of 1475

I would imagine MEDI-507 will be discussed: >>GAITHERSBURG, Md., Oct. 5 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI - news) announced today that it will present at the UBS Warburg Global Life Sciences Conference at 10:40 a.m. EDT on Tuesday, October 9, 2001. The conference is being held at the Pierre Hotel in New York City from October 8-12, 2001. Listen only telephone conference lines have been set up for public access to hear the presentations. For more information regarding this presentation, visit the UBS Warburg website at ubswarburg.com .<< snip Cheers, Tuck

To: nigel bates who wrote (1038)	10/17/2001 7:19:18 AM
From: Arthur Radley	Respond to of 1475

Concerning the Techvest conference that BTRN will be presenting next week, the following info taken from a Yahoo poster... upcoming conference by: soldier30 10/16/01 10:19 pm Msg: 1245 of 1247 At Techvest, the focus is on regenerative medicine, so BTRN will presumably highlight the importance of tolerance strategies for all efforts at using allogeneic cells and tissues for regeneration and repair--Presumably, the critical importance of MEDI-507 will be highlighted as will its unique multi-mechanistic effects at different doses-- in addition, stem cell sciences is also presenting, so we'll have an opportunity to finally appreciate what these 2 companies have been up to in this area of research-- Upon recent conversation with the CEO, I get the sense of increased excitement with the company's internal successes and steadily positive morale--there's frustration about the stock price but confidence that the stunningly depressed valuation will shortly become substantially less depressed.....